377 related articles for article (PubMed ID: 22227571)
41. IDO metabolite produced by EBV-transformed B cells inhibits surface expression of NKG2D in NK cells via the c-Jun N-terminal kinase (JNK) pathway.
Song H; Park H; Kim J; Park G; Kim YS; Kim SM; Kim D; Seo SK; Lee HK; Cho D; Hur D
Immunol Lett; 2011 May; 136(2):187-93. PubMed ID: 21277902
[TBL] [Abstract][Full Text] [Related]
42. IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA.
Kloess S; Huenecke S; Piechulek D; Esser R; Koch J; Brehm C; Soerensen J; Gardlowski T; Brinkmann A; Bader P; Passweg J; Klingebiel T; Schwabe D; Koehl U
Eur J Immunol; 2010 Nov; 40(11):3255-67. PubMed ID: 21061445
[TBL] [Abstract][Full Text] [Related]
43. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA.
Li P; Morris DL; Willcox BE; Steinle A; Spies T; Strong RK
Nat Immunol; 2001 May; 2(5):443-51. PubMed ID: 11323699
[TBL] [Abstract][Full Text] [Related]
44. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD
J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537
[TBL] [Abstract][Full Text] [Related]
45. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.
Zhu S; Denman CJ; Cobanoglu ZS; Kiany S; Lau CC; Gottschalk SM; Hughes DP; Kleinerman ES; Lee DA
Pharm Res; 2015 Mar; 32(3):779-92. PubMed ID: 24203492
[TBL] [Abstract][Full Text] [Related]
46. NKG2D functions as an activating receptor on natural killer cells in the common marmoset (Callithrix jacchus).
Watanabe M; Kudo Y; Kawano M; Nakayama M; Nakamura K; Kameda M; Ebara M; Sato T; Nakamura M; Omine K; Kametani Y; Suzuki R; Ogasawara K
Int Immunol; 2014 Nov; 26(11):597-606. PubMed ID: 24860119
[TBL] [Abstract][Full Text] [Related]
47. Palmitoylation of MICA, a ligand for NKG2D, mediates its recruitment to membrane microdomains and promotes its shedding.
Agüera-González S; Gross CC; Fernández-Messina L; Ashiru O; Esteso G; Hang HC; Reyburn HT; Long EO; Valés-Gómez M
Eur J Immunol; 2011 Dec; 41(12):3667-76. PubMed ID: 21928280
[TBL] [Abstract][Full Text] [Related]
48. NKG2D and Related Immunoreceptors.
Strong RK; McFarland BJ
Adv Protein Chem; 2004; 68():281-312. PubMed ID: 15500864
[TBL] [Abstract][Full Text] [Related]
49. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
50. Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer.
Huang B; Sikorski R; Sampath P; Thorne SH
J Immunother; 2011 Apr; 34(3):289-96. PubMed ID: 21389869
[TBL] [Abstract][Full Text] [Related]
51. MMP9 mediates MICA shedding in human osteosarcomas.
Sun D; Wang X; Zhang H; Deng L; Zhang Y
Cell Biol Int; 2011 Jun; 35(6):569-74. PubMed ID: 21143201
[TBL] [Abstract][Full Text] [Related]
52. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
Front Immunol; 2018; 9():1282. PubMed ID: 29963042
[TBL] [Abstract][Full Text] [Related]
53. A disease-linked
Zuo J; Willcox CR; Mohammed F; Davey M; Hunter S; Khan K; Antoun A; Katakia P; Croudace J; Inman C; Parry H; Briggs D; Malladi R; Willcox BE; Moss P
Sci Signal; 2017 May; 10(481):. PubMed ID: 28559451
[TBL] [Abstract][Full Text] [Related]
54. The histone deacetylase inhibitor SAHA simultaneously reactivates HIV-1 from latency and up-regulates NKG2D ligands sensitizing for natural killer cell cytotoxicity.
Desimio MG; Giuliani E; Doria M
Virology; 2017 Oct; 510():9-21. PubMed ID: 28689087
[TBL] [Abstract][Full Text] [Related]
55. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family.
Steinle A; Li P; Morris DL; Groh V; Lanier LL; Strong RK; Spies T
Immunogenetics; 2001; 53(4):279-87. PubMed ID: 11491531
[TBL] [Abstract][Full Text] [Related]
56. Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis.
Zhang C; Wang Y; Zhou Z; Zhang J; Tian Z
Cancer Immunol Immunother; 2009 Aug; 58(8):1275-85. PubMed ID: 19139882
[TBL] [Abstract][Full Text] [Related]
57. Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor.
López-Soto A; Huergo-Zapico L; Galván JA; Rodrigo L; de Herreros AG; Astudillo A; Gonzalez S
J Immunol; 2013 Apr; 190(8):4408-19. PubMed ID: 23509364
[TBL] [Abstract][Full Text] [Related]
58. N-glycosylation of asparagine 8 regulates surface expression of major histocompatibility complex class I chain-related protein A (MICA) alleles dependent on threonine 24.
Mellergaard M; Skovbakke SL; Schneider CL; Lauridsen F; Andresen L; Jensen H; Skov S
J Biol Chem; 2014 Jul; 289(29):20078-91. PubMed ID: 24872415
[TBL] [Abstract][Full Text] [Related]
59. Vesicular stomatitis virus infection promotes immune evasion by preventing NKG2D-ligand surface expression.
Jensen H; Andresen L; Nielsen J; Christensen JP; Skov S
PLoS One; 2011; 6(8):e23023. PubMed ID: 21857986
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of MMP activity can restore NKG2D ligand expression in gastric cancer, leading to improved NK cell susceptibility.
Shiraishi K; Mimura K; Kua LF; Koh V; Siang LK; Nakajima S; Fujii H; Shabbir A; Yong WP; So J; Takenoshita S; Kono K
J Gastroenterol; 2016 Dec; 51(12):1101-1111. PubMed ID: 27002316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
